Cancer Clinical Trial
Official title:
Expanding Access to Home-Based Palliative Care Through Primary Care Medical Groups
This study will test the effectiveness of integrating an evidence-based model of home-based palliative (HBPC) within primary care clinics on patient and caregiver outcomes. The investigators will conduct a randomized controlled trial, randomizing 1,155 seriously ill patients (and approximately 884 family caregivers) who receive primary care from 30-40 regional accountable care organizations (ACOs) in California to one of two study groups: HBPC or enhanced usual care (EUC). Follow-up data will be collected via telephone surveys with patients at 1- and 2-months and with caregivers at 1- and 2-months, and, as appropriate, following the death of the patient.
Background and Significance
Patients with serious illness from cancer, heart failure (HF), and chronic obstructive
pulmonary disease (COPD) often receive poor quality of care, resulting in unmitigated pain
and related symptoms, unmet psychosocial needs, and significant caregiver burden. Palliative
care, a patient-centered approach that provides pain and symptom management and psychosocial
and spiritual support, has strong evidence for improved outcomes for these seriously ill
patients. Palliative care differs from hospice in that it is offered early in the illness
course and in conjunction with other therapies intended to prolong life. Most palliative care
programs are hospital-based; few offer care at home, where patients spend the most time and
require the most support.
Study Aims
This study will test the effectiveness of integrating an evidence-based model of home-based
palliative (HBPC) within primary care clinics on patient and caregiver outcomes. The
investigators will conduct a randomized controlled trial, randomizing 1,155 seriously ill
patients (and approximately 884 family caregivers) who receive primary care from 30-40
regional accountable care organizations (ACOs) in California to one of two study groups: HBPC
or enhanced usual care (EUC). Follow-up data will be collected via telephone surveys with
patients at 1- and 2-months and with caregivers at 1- and 2-months, and, as appropriate,
following the death of the patient.
The study's specific aims are:
- Specific Aim 1: Determine differences in improvement on measures of physical and
psychological well-being between patients receiving HBPC and patients receiving enhanced
usual care (EUC).
- Specific Aim 2: Determine differences in survival time between patients receiving HBPC
and patients receiving EUC.
- Specific Aim 3: Determine differences in number of emergency department (ED) visits and
hospital admissions between patients receiving HBPC and patients receiving EUC.
- Specific Aim 4: Determine differences in improvement on patient-provider communication
between patients receiving HBPC and patients receiving EUC.
- Specific Aim 5: Determine differences in improvement on psychosocial outcomes between
caregivers of patients receiving HBPC and caregivers of patients receiving EUC.
Study Description
Study Population. The study will enroll 1,155 patients and approximately 883 caregivers from
primary care medical groups operating under ACO contracts with Blue Shield of California
(Blue Shield), the study's insurance partner. About 75% of patients will be age 65 or older;
about 55% will be female. About 45% of patients will be ethnic minority members,
predominantly of Hispanic decent.
Comparators. The study will compare outcomes from two groups: patients who receive EUC (with
usual care enhanced by: 1) provider training in palliative care; 2) case management for EUC
patients; and 3) provider support through palliative care consultation) and patients who
receive HBPC provided by an HBPC team. HBPC features home visits by an interdisciplinary PC
team (physician, nurse, social worker, and chaplain) that provides pain and symptom
management, psychosocial support, advance care planning, disease management education,
spiritual and grief counseling, and other services as needed.
Outcomes. Primary outcomes are change in patient pain, symptoms, depression, and anxiety.
These measures will be collected via patient self-report at baseline and at one- and
two-months following enrollment. Change in survival, ED visits, and hospital episodes
(including length of stay, when applicable) also are primary outcomes that will be collected
from the electronic medical record (EMR). These data will be collected following patient
death or at study's end. Secondary patient outcomes are peace, patient-physician
communication, and hope.Secondary caregiver outcomes are change in caregiver depression,
anxiety, burden, and patient-physician communication, with these assessments all collected at
baseline and one- and two-months following enrollment. Caregiver's experience of patient
death will be collected one month following patient death, when applicable.
Analytic Methods. Investigation of the main effect of HBPC and EUC on outcomes will be
conducted at each follow-up and then on the longitudinal trend. Baseline outcome measures
will be treated as covariates to control for potential baseline differences. Repeated
measures analyses will be used to investigate the longitudinal effects of program conditions
on outcome measures. Sub-analyses will examine outcome differences by patient age, diagnosis,
and race.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|